Dewar R L, Highbarger H C, Sarmiento M D, Todd J A, Vasudevachari M B, Davey R T, Kovacs J A, Salzman N P, Lane H C, Urdea M S
Department of Microbiology, Georgetown University Medical Center, Washington, DC.
J Infect Dis. 1994 Nov;170(5):1172-9. doi: 10.1093/infdis/170.5.1172.
A branched DNA (bDNA)-based quantitation of plasma human immunodeficiency virus type 1 (HIV-1) RNA was used to monitor the virologic status of 102 patients (29-906 CD4 cells/mm3) enrolled in clinical trials of antiretroviral and immune-based therapies. Virion-associated RNA was measurable in plasma of 74% of patients tested (10,000-10,000,000 RNA equivalents/mL). Virus levels measured by the bDNA assay exceeded titers obtained by quantitative plasma culture and were inversely correlated (r = -.378; P < .05) with total CD4 cell counts. The assay was used to demonstrate a significant decline (mean, 5-fold; range, 0- to 30-fold), relative to pretreatment, in virus load after beginning antiviral therapy and a transient increase (mean, 15-fold; range, 2- to 50-fold) after treatment with interleukin-2. The decrease in RNA was more dramatic than changes in serum p24 antigen. The bDNA assay yields reproducible results, is relatively easy, and should be useful in measuring HIV-1 RNA in patients in clinical trials.
基于分支DNA（bDNA）的血浆人类免疫缺陷病毒1型（HIV-1）RNA定量分析，用于监测102例（CD4细胞计数为29 - 906个/mm³）参与抗逆转录病毒和免疫疗法临床试验患者的病毒学状态。在74%接受检测的患者血浆中可检测到病毒体相关RNA（10,000 - 10,000,000 RNA当量/mL）。通过bDNA分析测得的病毒水平超过了定量血浆培养获得的滴度，且与总CD4细胞计数呈负相关（r = -0.378；P < 0.05）。该分析方法用于证明开始抗病毒治疗后，相对于治疗前病毒载量显著下降（平均5倍；范围0至30倍），以及白细胞介素-2治疗后短暂升高（平均15倍；范围2至50倍）。RNA的下降比血清p24抗原的变化更为显著。bDNA分析产生可重复的结果，相对简便，在临床试验中测量患者的HIV-1 RNA方面应具有实用价值。
